Duncan I Jodrell

List of Publications by Year
in descending order

22 papers	1,997 citations	759233 12 h-index	713466 21 g-index
22 all docs	22 docs citations	22 times ranked	4836 citing authors

#	Article	IF	Citations
1	Early Neutrophilia Marked by Aerobic Glycolysis Sustains Host Metabolism and Delays Cancer Cachexia. Cancers, 2022, 14, 963.	3.7	9
2	Abstract 6103: Reshaping the myeloid-dependent pro-tumorigenic microenvironment in PDAC by targeting the extracellular adenosine pathway: A therapeutic opportunity. Cancer Research, 2022, 82, 6103-6103.	0.9	0
3	Mechanisms Underlying Vascular Endothelial Growth Factor Receptor Inhibition–Induced Hypertension. Hypertension, 2021, 77, 1591-1599.	2.7	13
4	Quantifying cell cycle-dependent drug sensitivities in cancer using a high throughput synchronisation and screening approach. EBioMedicine, 2021, 68, 103396.	6.1	9
5	T Cell–Mediated Antitumor Immunity Cooperatively Induced By TGFβR1 Antagonism and Gemcitabine Counteracts Reformation of the Stromal Barrier in Pancreatic Cancer. Molecular Cancer Therapeutics, 2021, 20, 1926-1940.	4.1	9
6	Complete loss of ATM function augments replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic cancer models. British Journal of Cancer, 2020, 123, 1424-1436.	6.4	40
7	Early relapse on adjuvant gemcitabine associated with an exceptional response to 2nd line capecitabine chemotherapy in a patient with pancreatic adenosquamous carcinoma with strong intra-tumoural expression of cytidine deaminase: a case report. BMC Cancer, 2020, 20, 38.	2.6	6
8	Multicenter Validation of the CamGFR Model for Estimated Glomerular Filtration Rate. JNCI Cancer Spectrum, 2019, 3, pkz068.	2.9	6
9	Targeting melanoma's MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors. Nature Communications, 2019, 10, 5167.	12.8	52
10	Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer. Clinical Cancer Research, 2019, 25, 6742-6755.	7.0	45
11	Loss of the interleukin-6 receptor causes immunodeficiency, atopy, and abnormal inflammatory responses. Journal of Experimental Medicine, 2019, 216, 1986-1998.	8.5	153
12	Cancer Immunotherapy Trials Underutilize Immune Response Monitoring. Oncologist, 2018, 23, 116-117.	3.7	3
13	The ATR Inhibitor AZD6738 Synergizes with Gemcitabine *In Vitro* and *In Vivo* to Induce Pancreatic Ductal Adenocarcinoma Regression. Molecular Cancer Therapeutics, 2018, 17, 1670-1682.	4.1	79
14	Modelling of the cancer cell cycle as a tool for rational drug development: A systems pharmacology approach to cyclotherapy. PLoS Computational Biology, 2017, 13, e1005529.	3.2	12
15	New Model for Estimating Glomerular Filtration Rate in Patients With Cancer. Journal of Clinical Oncology, 2017, 35, 2798-2805.	1.6	78
16	Combenefit: an interactive platform for the analysis and visualization of drug combinations. Bioinformatics, 2016, 32, 2866-2868.	4.1	499
17	Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity. Cell Metabolism, 2016, 24, 672-684.	16.2	264
18	Understanding the Complexity of Porous Graphitic Carbon (PGC) Chromatography: Modulation of Mobile-Stationary Phase Interactions Overcomes Loss of Retention and Reduces Variability. Analytical Chemistry, 2016, 88, 6190-6194.	6.5	59

#	ARTICLE	IF	CITATIONS
19	The use of error-category mapping in pharmacokinetic model analysis of dynamic contrast-enhanced MRI data. Magnetic Resonance Imaging, 2015, 33, 246-251.	1.8	1
20	Design, Synthesis, and Biological Evaluation of an Allosteric Inhibitor of HSET that Targets Cancer Cells with Supernumerary Centrosomes. Chemistry and Biology, 2013, 20, 1399-1410.	6.0	94
21	CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 12325-12330.	7.1	207
22	*nab*-Paclitaxel Potentiates Gemcitabine Activity by Reducing Cytidine Deaminase Levels in a Mouse Model of Pancreatic Cancer. Cancer Discovery, 2012, 2, 260-269.	9.4	359